JPH0733385B2 - 物質ｐの拮抗薬としてのｎ−アルキルキヌクリジニウム塩 - Google Patents

物質ｐの拮抗薬としてのｎ−アルキルキヌクリジニウム塩

Info

Publication number
JPH0733385B2
JPH0733385B2 JP4501342A JP50134292A JPH0733385B2 JP H0733385 B2 JPH0733385 B2 JP H0733385B2 JP 4501342 A JP4501342 A JP 4501342A JP 50134292 A JP50134292 A JP 50134292A JP H0733385 B2 JPH0733385 B2 JP H0733385B2
Authority
JP
Japan
Prior art keywords
formula
alkyl
compound
substance
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP4501342A
Other languages
English (en)
Japanese (ja)
Other versions
JPH05508866A (ja
Inventor
ロウ，ジヨン・エイ・ザ・サード
Original Assignee
フアイザー・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フアイザー・インコーポレイテツド filed Critical フアイザー・インコーポレイテツド
Publication of JPH05508866A publication Critical patent/JPH05508866A/ja
Publication of JPH0733385B2 publication Critical patent/JPH0733385B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP4501342A 1991-01-10 1991-12-04 物質ｐの拮抗薬としてのｎ−アルキルキヌクリジニウム塩 Expired - Lifetime JPH0733385B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63964491A 1991-01-10 1991-01-10
US639,644 1991-01-10
PCT/US1991/008836 WO1992012151A1 (fr) 1991-01-10 1991-12-04 Sels de n-alkyle quinuclidinium utilises comme antagonistes de substance p

Publications (2)

Publication Number Publication Date
JPH05508866A JPH05508866A (ja) 1993-12-09
JPH0733385B2 true JPH0733385B2 (ja) 1995-04-12

Family

ID=24564973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4501342A Expired - Lifetime JPH0733385B2 (ja) 1991-01-10 1991-12-04 物質ｐの拮抗薬としてのｎ−アルキルキヌクリジニウム塩

Country Status (14)

Country Link
EP (1) EP0566589A1 (fr)
JP (1) JPH0733385B2 (fr)
KR (1) KR930703311A (fr)
AU (1) AU652407B2 (fr)
CA (1) CA2100163A1 (fr)
FI (1) FI933167A7 (fr)
HU (1) HUT65612A (fr)
IE (1) IE920071A1 (fr)
IL (1) IL100584A (fr)
MX (1) MX9200057A (fr)
NZ (1) NZ241261A (fr)
PT (1) PT100003A (fr)
WO (1) WO1992012151A1 (fr)
ZA (1) ZA92148B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
JPH072740B2 (ja) * 1990-06-01 1995-01-18 フアイザー・インコーポレイテツド ３―アミノ―２―アリールキヌクリジン
DK0613458T3 (da) * 1991-11-12 1998-02-09 Pfizer Acykliske ethylendiaminderivater som substans P receptorantagonister
EP0641328B1 (fr) * 1992-05-18 2001-11-21 Pfizer Inc. Derives aza-bicycliques en pont utiles comme antagonistes de la substance p
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
AU4396193A (en) * 1992-08-04 1994-03-03 Pfizer Inc. 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
GB9216911D0 (en) * 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
KR100821410B1 (ko) 2000-07-11 2008-04-10 에이엠알 테크놀로지, 인크. 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1940842B1 (fr) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AU2009222122A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2010132437A1 (fr) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryle, hétéroaryle et tétrahydroisoquinolines à hétérocycle substitué et leur utilisation
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
EP3330377A1 (fr) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (fr) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
EP3525785B1 (fr) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Inhibiteurs de kdm5
EP3706747B1 (fr) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (fr) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Inhibiteurs de prmt5

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1173445B (it) * 1984-03-16 1987-06-24 Guidotti & C Spa Labor Agenti ad attivita' antibroncospastica e composizioni farmaceutiche che li contengono
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo

Also Published As

Publication number Publication date
JPH05508866A (ja) 1993-12-09
IL100584A (en) 1995-10-31
MX9200057A (es) 1992-07-01
HUT65612A (en) 1994-07-28
AU652407B2 (en) 1994-08-25
CA2100163A1 (fr) 1992-07-11
KR930703311A (ko) 1993-11-29
IE920071A1 (en) 1992-07-15
PT100003A (pt) 1993-02-26
ZA92148B (en) 1993-07-09
FI933167A0 (fi) 1993-07-09
AU9094791A (en) 1992-08-17
FI933167L (fi) 1993-07-09
IL100584A0 (en) 1992-09-06
NZ241261A (en) 1994-05-26
FI933167A7 (fi) 1993-07-09
EP0566589A1 (fr) 1993-10-27
WO1992012151A1 (fr) 1992-07-23
HU9301988D0 (en) 1993-12-28

Similar Documents

Publication Publication Date Title
JPH0733385B2 (ja) 物質ｐの拮抗薬としてのｎ−アルキルキヌクリジニウム塩
JP2531565B2 (ja) ３−アミノピペリジン誘導体及び関連する窒素含有複素環化合物
JP2614408B2 (ja) サブスタンスｐ受容体アンタゴニストとしての非環式エチレンジアミン誘導体
JP2757234B2 (ja) Ｐ物質拮抗薬としての架橋アザ二環式誘導体
JP7094989B2 (ja) シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト
PL172054B1 (pl) Sposób wytwarzania nowych pochodnych fluoroalkoksybenzyloaminowych zwiazków heterocyklicznych zawierajacych azot PL PL PL PL PL PL
JPH06507179A (ja) 縮合三環式窒素含有複素環
JPWO1994014769A1 (ja) Ｎ−置換インドール誘導体
RO110499B1 (ro) Derivati de chinuclidina si compozitie farmaceutica continand acesti compusi
JP2007508358A (ja) Ｎ−［フェニル（ピペリジン−２−イル）メチル］ベンズアミド誘導体、この調製方法およびこの治療法における使用
JPS6289679A (ja) ピペリジン誘導体
US20110318266A1 (en) Phthalimide derivative metabotropic glutamate r4 ligands
DE60036081T2 (de) (1-phenacyl-3-phenyl-3-piperidylethyl)piperidinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
JPH0725736B2 (ja) トランス−ピペリジン−２，５−ジカルボキシレートの製法
JP2753146B2 (ja) ビス−アザー二環式抗不安薬の製法および中間体
FR2581064A1 (fr) Derive antipsychotique a base de 8-(4-(4-(1-exo-1,2-benzisothiazol-3-yl)-1-piperazinyl)-butyl)-8-azaspiro(4,5)decane-7,9-dione et son procede de preparation
JPH05506440A (ja) アルコキシ置換ジヒドロベンゾピラン―２―カルボン酸およびその誘導体
EP0405784A1 (fr) Nouveaux dérivés benzisoquinoléiniques
JPS5857380A (ja) ９，１０−置換２−メシチルイミノ−３−アルキル−３，４，６，７−テトラヒドロ−２Ｈ−ピリミド（６．１−ａ）イソキノリン−４−オン
JPS58177980A (ja) 新規なベンズイソオキサゾ−ル誘導体
JPS6112662A (ja) ジヒドロピリジン誘導体及びその製法
PT96142B (pt) Processo para a preparacao de derivados de 3-fenilglutarimida antagonistas de receptores muscarinicos
CN117050055A (zh) 含有酰胺吡啶环的化合物
JPS61158968A (ja) フエナシル誘導体
KR100611262B1 (ko) (1-페나시-3-페닐-3-피페리딜에틸)피페리딘 유도체, 그의제조 방법 및 이를 함유하는 제약 조성물